<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yan Y</submitter><funding>Fundamental Research Funds for the Central Universities</funding><funding>Huazhong Agricultural University Startup</funding><funding>National Key R&amp;amp;D Plan</funding><funding>Youth 1000 Plan Project</funding><pagination>494-504</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6495079</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16</volume><pubmed_abstract>MicroRNAs (miRNAs) act as regulators of aging at the tissue or organism level or as regulators of cellular senescence. Targeted deletion of miR-126 in mice causes partial embryonic lethality, but its biological function in the liver is still largely unknown. Here, we deleted miR-126a, using the CRISPR/Cas9 system in vitro and in vivo. miR-126a was reduced in the aging livers, and disruption of miR-126a in bone mesenchymal stem cells (BMSCs) induced age-associated telomere shortening, DNA damage responses, and proinflammatory cytokines. Moreover, disruption of miR-126a in mice caused hepatocyte senescence, inflammation, and metabolism deficiency. In addition, disruption of miR-126a via BMSC transplantation aggravated the severity of liver defects induced by cholestasis compared with that in the functional miR-126a BMSC group. Mechanistically, we identified versican (VCAN) as a novel direct miR-126a-5p target that induces telomere shortening, BMSC senescence, and nuclear factor κB (NF-κB) pathway activation. This study identified aging-related reduced expression of miR-126a and promotion of its target VCAN as a key mechanism in the regulation of hepatic metabolic function during aging and hepatic damage by inducing NF-κB pathway activation, DNA repair function disorder, and telomere attrition. The findings indicate that miR-126a may be a drug target for the treatment of hepatic failure.</pubmed_abstract><journal>Molecular therapy. Nucleic acids</journal><pubmed_title>Deletion of miR-126a Promotes Hepatic Aging and Inflammation in a Mouse Model of Cholestasis.</pubmed_title><pmcid>PMC6495079</pmcid><funding_grant_id>2017YFA0103202</funding_grant_id><funding_grant_id>2662017PY106</funding_grant_id><funding_grant_id>2662016PY087</funding_grant_id><funding_grant_id>2017YFA0103200</funding_grant_id><funding_grant_id>2662019YJ008</funding_grant_id><pubmed_authors>Huang W</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Wu D</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Yan Y</pubmed_authors><pubmed_authors>Qin D</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Hu B</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deletion of miR-126a Promotes Hepatic Aging and Inflammation in a Mouse Model of Cholestasis.</name><description>MicroRNAs (miRNAs) act as regulators of aging at the tissue or organism level or as regulators of cellular senescence. Targeted deletion of miR-126 in mice causes partial embryonic lethality, but its biological function in the liver is still largely unknown. Here, we deleted miR-126a, using the CRISPR/Cas9 system in vitro and in vivo. miR-126a was reduced in the aging livers, and disruption of miR-126a in bone mesenchymal stem cells (BMSCs) induced age-associated telomere shortening, DNA damage responses, and proinflammatory cytokines. Moreover, disruption of miR-126a in mice caused hepatocyte senescence, inflammation, and metabolism deficiency. In addition, disruption of miR-126a via BMSC transplantation aggravated the severity of liver defects induced by cholestasis compared with that in the functional miR-126a BMSC group. Mechanistically, we identified versican (VCAN) as a novel direct miR-126a-5p target that induces telomere shortening, BMSC senescence, and nuclear factor κB (NF-κB) pathway activation. This study identified aging-related reduced expression of miR-126a and promotion of its target VCAN as a key mechanism in the regulation of hepatic metabolic function during aging and hepatic damage by inducing NF-κB pathway activation, DNA repair function disorder, and telomere attrition. The findings indicate that miR-126a may be a drug target for the treatment of hepatic failure.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jun</publication><modification>2026-05-07T03:45:41.98Z</modification><creation>2025-05-18T12:51:13.738Z</creation></dates><accession>S-EPMC6495079</accession><cross_references><pubmed>31051334</pubmed><doi>10.1016/j.omtn.2019.04.002</doi></cross_references></HashMap>